Skip to main content
. Author manuscript; available in PMC: 2016 Oct 13.
Published in final edited form as: Br J Haematol. 2016 Aug 1;175(2):226–236. doi: 10.1111/bjh.14254

Fig 2.

Fig 2

Kaplan–Meier survival plots of AML patients with pretreatment DNMT3A R882 mutations by three DNMT3A complete remission groups (A) Disease-free survival. (B) Overall survival. Group 1 includes patients whose DNMT3A R882 mutations cleared below the variant allele frequency (VAF) cut-off of 3% in their remission sample and who had no other AML mutation. Group 2a includes patients with a DNMT3A R882 mutation with a VAF ≥3% in their remission sample but with clearance of all other AML mutations. Group 2b includes patients with a DNMT3A R882 mutation with a VAF ≥3% and ≥1 other AML mutation in their remission sample.